For the total GMP synthesis of complex carbohydrates and carbohydrate based medicinal chemistry, Dextra has a proven record of developing innovative solutions to minimise costs, reduce technology transfer issues and optimise robust route generation.
Custom Synthesis—from mgs to multi kg scale, core capabilities include: Process development, glycosylation, hydrogenation and conjugation chemistry.
Analytical Services—providing comprehensive analytical support for custom synthesis programs and independent analytical services
GMP API Manufacturing—to support Phase I and Phase II clinical trials in reactors up to 50 L
Dextra Catalogue—showcases a range of over 800 carbohydrate products, including neoglycoproteins, neoglycolipids, heparin derivatives, iminosugars, blood group products, oligosaccharides, glycans, building blocks and a range of rare sugars for glycobiology and reference standards.
Dextra also has the ability to transfer complex chemical processes to its large scale manufacturing parent, New Zealand Pharmaceuticals.